Novartis Cosentyx Secures Positive CHMP Opinion for Polymyalgia Rheumatica, a Modest Incremental Win

What happened

On September 21, 2026, Novartis received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Cosentyx (secukinumab) in polymyalgia rheumatica (PMR), supported by late-stage clinical data. This adds another inflammatory indication to Cosentyx's label beyond its existing uses, potentially broadening its patient pool in the EU. However, Cosentyx is not part of the priority growth brands highlighted in the latest DeepValue master report, which focused on Kisqali, Kesimpta, Pluvicto, Scemblix, and Leqvio as the offset engine to Entresto's patent cliff. The news does not address the core financial challenges reported for H1 2026: group sales down 2% in constant currency, operating margin falling to 32.6%, and free cash flow down 12%. While positive for the immunology franchise, the incremental revenue from PMR is likely modest relative to the company's scale and does not materially shift the investment thesis.

Implication

Investors should treat this CHMP opinion as an incremental regulatory milestone that strengthens Cosentyx's competitive position in immunology but does not alter the near-term earnings trajectory. The core investment debate remains whether Pluvicto's anticipated mHSPC approval and H2 2026 pipeline readouts can offset Entresto's generic erosion and justify the current 23.1x P/E. Cosentyx is already selected for Medicare price negotiation, and the PMR indication is a relatively small patient population, so revenue uplift is unlikely to be transformative. Current operating evidence does not support a premium multiple, with H1 2026 margins compressed and free cash flow declining. Maintain a WAIT stance and focus on Q3 2026 evidence of group-level stabilization and pipeline catalysts rather than this label expansion.

Thesis delta

The thesis remains predicated on replacing Entresto-era earnings with growth from priority brands and resolving H2 2026 catalysts such as Pluvicto approval and pelacarsen/remibrutinib readouts. This positive CHMP opinion for Cosentyx in PMR is a favorable but minor development that adds to the immunology franchise without addressing the core patent-cliff and margin compression issues. No material shift in valuation or conviction is warranted from this event alone.